scPharmaceuticals’ (SCPH) “Buy” Rating Reaffirmed at HC Wainwright

scPharmaceuticals (NASDAQ:SCPH)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 227.87% from the stock’s previous close.

scPharmaceuticals Stock Down 5.8 %

Shares of SCPH traded down $0.34 during trading hours on Thursday, reaching $5.49. The company’s stock had a trading volume of 193,030 shares, compared to its average volume of 237,665. The company has a 50 day moving average of $5.61 and a two-hundred day moving average of $5.93. The company has a quick ratio of 8.88, a current ratio of 7.08 and a debt-to-equity ratio of 1.04. The firm has a market cap of $197.91 million, a price-to-earnings ratio of -3.87 and a beta of 0.08. scPharmaceuticals has a 1-year low of $4.63 and a 1-year high of $12.75.

Institutional Investors Weigh In On scPharmaceuticals

A number of institutional investors have recently modified their holdings of SCPH. Virtu Financial LLC acquired a new stake in scPharmaceuticals during the second quarter valued at $53,000. IPG Investment Advisors LLC acquired a new stake in shares of scPharmaceuticals during the 4th quarter valued at about $75,000. Cubist Systematic Strategies LLC bought a new stake in shares of scPharmaceuticals in the 3rd quarter valued at approximately $75,000. AQR Capital Management LLC bought a new position in scPharmaceuticals during the third quarter valued at approximately $77,000. Finally, BNP Paribas Arbitrage SNC raised its position in scPharmaceuticals by 348.5% during the second quarter. BNP Paribas Arbitrage SNC now owns 7,633 shares of the company’s stock valued at $78,000 after acquiring an additional 5,931 shares in the last quarter. Institutional investors and hedge funds own 79.60% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.